Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene

Pelosi, Giuseppe; Gasparini, Patrizia; Cavazza, Alberto; Rossi, Giulio; Graziano, Paolo; Barbareschi, Mattia; Perrone, Francesco; Barberis, Massimo; Takagi, Masayuki; Kunimura, Toshiaki; Yamada, Tetsuya; Nakatani, Yukio; Pastorino, Ugo; Scanagatta, Paolo; Sozzi, Gabriella; Garassino, Marina Chiara; Braud, Filippo de; Papotti, Mauro

doi:10.1016/j.lungcan.2012.05.093

Cited by 68 publications

(49 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our case, a positive expression of TTF-1 was not observed in the metastatic adrenal lesion, whereas the primary lung tumor did show positive TTF-1 immunostaining. Although a case of ALK rearrangement in primary lung pleomorphic carcinoma was reported by Pelosi et al (5), to our knowledge, there are no reports of metastatic pleomorphic carcinoma harboring ALK rearrangement. Furthermore, we concluded that the adrenal lesion in this case was a metastatic tumor based on the observed ALK rearrangement.…”

Section: Discussionmentioning

confidence: 73%

Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma

et al. 2015

View full text Add to dashboard Cite

A 55-year-old woman was diagnosed with a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) rearrangement-positive lung adenocarcinoma and treated with chemotherapy consisting of crizotinib, a tyrosine kinase inhibitor of ALK, as second-line chemotherapy. However, the size of the metastatic adrenal lesion increased, and the patient died due to multiple organ failure. An autopsy report revealed that the metastatic lesion of the adrenal tumor was ALK rearrangement-positive pleomorphic carcinoma. The epithelialmesenchymal transition (EMT) marker vimentin was immunohistochemically positive in both the lung and adrenal lesions. The present case report suggests the possibility of transformation into pleomorphic carcinoma as a result of EMT in patients with ALK rearrangement-positive lung cancer.

show abstract

Section: Discussionmentioning

confidence: 73%

Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…As for SCs, several reports have previously investigated the EGFR mutation status [2][3][4][5]. Studies by Italiano and Pelosi reported that no mutations of the EGFR gene were observed in 22 and 23 cases of lung SC, respectively [2,3]. In contrast, there exist two reports identifying EGFR mutations in patients with lung SC [4,5].…”

Section: Discussionmentioning

confidence: 99%

“…Although several reports have previously investigated genetic alterations in patients with SC [2][3][4][5], no mutations in oncogenic drivers of carcinosarcoma, including epidermal growth factor receptor (EGFR), have been identified. We herein report the case of a 61-year-old female referred for a detailed examination of a left pulmonary mass shadow.…”

Section: Introductionmentioning

confidence: 99%

The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene

et al. 2013

Self Cite

View full text Add to dashboard Cite

“…In a retrospective analysis of 20 pulmonary sarcomatoid carcinomas (PSC), the frequency of ALK-CNG was significantly higher compared to NSCLC with adenocarcinoma histology (22 % versus 0.02 %) with a mean copy number gain of 7 and a significant association with chromosome 7 (EGFR) and 17 (HER2) polysomy. This finding suggests the implication of ALK-CNG as an oncogenic event in PSC, potentially correlated with epithelial-mesenchymal transition and sarcomatoid differentiation [31]. Future confirmation of the oncogenic role of ALK-CNG could support the design of selective studies exploring the potential activity of the ALK inhibition in PSC.…”

Section: Discussionmentioning

confidence: 82%

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations

et al. 2016

View full text Add to dashboard Cite

BackgroundThe correlation between ALK gene copy number gain (ALK-CNG) and prognosis in the context of advanced non-small-cell lung cancer (NSCLC) remains a controversial issue. This study aimed to evaluate the association among ALK-CNG according to Fluorescent In Situ Hybridization (FISH), clinical characteristics and survival in resectable and advanced NSCLC.MethodsClinical and pathological data of patients with resectable and advanced NSCLC were retrospectively collected. Tumor tissues were analyzed for ALK-CNG by FISH, and patients were divided in 3 groups/patterns on the basis of ALK signals: disomic [Pattern A], 3–7 signals [Pattern B], >7 signals [Pattern C]. The association between clinical and pathological features and ALK-CNG patterns was evaluated. Disease/progression-free and overall survival (DFS/PFS and OS) were estimated using the Kaplan-Meyer method.ResultsA number of 128 (76.6 %) out of the 167 eligible patients were evaluable for ALK-CNG, displaying pattern A, B and C in 71 (42.5 %), 42 (25.1 %) and 15 (9 %) patients, respectively. Gains in ALK-CNG appear to be more frequent in smokers/former smokers than in non-smokers (74.2 % versus 20.4 %, respectively, p = 0.03). Pattern A and C seem more frequently associated with higher T-stage (T3-4), while pattern B appears more represented in lower T-stage (T 1-2) (p = 0.06). No significant differences in survival rate were observed among the above groups.ConclusionsA high ALK-CNG pattern might be associated with smoking status and theoretically it might mirror genomic instability. The implications for prognosis should be prospectively investigated and validated in larger patients’ series.Trial registrationWe confirm that all the study was performed in accordance with relevant guidelines and regulations and that all the protocol (part of a larger project MFAG 2013 N.14282) was approved by the local Ethics Committee of the Azienda Ospedaliera Universitaria Integrata of Verona on November 11st, 2014.

show abstract

Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene

Cited by 68 publications

References 40 publications

Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma

Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma

The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations

Contact Info

Product

Resources

About